|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1998-8-12
|
|
pubmed:abstractText |
To model the cost-effectiveness (CE) of granulocyte colony-stimulating factor (G-CSF) in early-stage breast cancer when its use is directed to those most in need of the medication.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2435-44
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9667261-Breast Neoplasms,
pubmed-meshheading:9667261-Cost-Benefit Analysis,
pubmed-meshheading:9667261-Dose-Response Relationship, Drug,
pubmed-meshheading:9667261-Female,
pubmed-meshheading:9667261-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9667261-Humans,
pubmed-meshheading:9667261-Models, Economic,
pubmed-meshheading:9667261-Neoplasm Staging,
pubmed-meshheading:9667261-Sensitivity and Specificity,
pubmed-meshheading:9667261-Survival Analysis,
pubmed-meshheading:9667261-Treatment Outcome,
pubmed-meshheading:9667261-United States
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.
|
|
pubmed:affiliation |
University of Pennsylvania Cancer Center and the Leonard Davis Institute of Health Economics, Department of Pediatrics, School of Medicine, Philadelphia, USA. silberj@wharton.upenn.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
